Literature DB >> 17437418

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.

J Dillner1, M Arbyn, L Dillner.   

Abstract

Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more rare cancers, namely cancer of the vulva, vagina, penis, anus, oropharynx and larynx. Effective prophylactic vaccines have been developed. In this review, we briefly address immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17437418      PMCID： PMC1868871          DOI： 10.1111/j.1365-2249.2007.03384.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  71 in total

1.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

2.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.

Authors:  Z Wang; N Christensen; J T Schiller; J Dillner
Journal:  J Gen Virol       Date:  1997-09       Impact factor: 3.891

4.  Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

Authors:  W I White; S D Wilson; F J Palmer-Hill; R M Woods; S J Ghim; L A Hewitt; D M Goldman; S J Burke; A B Jenson; S Koenig; J A Suzich
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

Authors:  J Ryding; L Dahlberg; M Wallen-Ohman; J Dillner
Journal:  J Gen Virol       Date:  2007-03       Impact factor: 3.891

6.  Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.

Authors:  N D Christensen; N M Cladel; C A Reed; L R Budgeon; M E Embers; D M Skulsky; W L McClements; S W Ludmerer; K U Jansen
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

7.  Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.

Authors:  J Dillner; I Kallings; C Brihmer; B Sikström; P Koskela; M Lehtinen; J T Schiller; M Sapp; P A Mårdh
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

10.  Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.

Authors:  Ruanne V Barnabas; Päivi Laukkanen; Pentti Koskela; Osmo Kontula; Matti Lehtinen; Geoff P Garnett
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069
View more
  9 in total

1.  MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.

Authors:  Partha Basu; Puneet Chandna; R N K Bamezai; Maqsood Siddiqi; Dhananjaya Saranath; Adrian Lear; Sam Ratnam
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

2.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

3.  Multiple human papillomavirus infections and type competition in men.

Authors:  Anne F Rositch; Charles Poole; Michael G Hudgens; Kawango Agot; Edith Nyagaya; Stephen Moses; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith
Journal:  J Infect Dis       Date:  2011-11-04       Impact factor: 5.226

4.  Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types.

Authors:  David P Durham; Eric M Poolman; Yoko Ibuka; Jeffrey P Townsend; Alison P Galvani
Journal:  J Infect Dis       Date:  2012-08-07       Impact factor: 5.226

5.  Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.

Authors:  Anne F Rositch; Michael G Hudgens; Danielle M Backes; Stephen Moses; Kawango Agot; Edith Nyagaya; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith
Journal:  J Infect Dis       Date:  2012-06-18       Impact factor: 5.226

6.  Does intention to recommend HPV vaccines impact HPV vaccination rates?

Authors:  Kristen A Feemster; Maria Middleton; Alexander G Fiks; Sarah Winters; Sara B Kinsman; Jessica A Kahn
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

7.  Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.

Authors:  Anna Söderlund-Strand; Joyce Carlson; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

8.  Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.

Authors:  Mona Saraiya; Marc T Goodman; S Deblina Datta; Vivien W Chen; Phyllis A Wingo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.